3rd IAS Conference on HIV Pathogenesis and Treatment. Poster Number Abstract #
|
|
- Gwen Newman
- 5 years ago
- Views:
Transcription
1 3rd IAS Conference on HIV Pathogenesis and Treatment July 2005, Rio de Janeiro, Brazil Poster Number Abstract # TuFo0106 TuFo0106 Characterization of Anemia in HIV-infected (HIV+) Subjects Treated with Antiretroviral Therapy (ART) With and Without Zidovudine (+/- ZDV) in 54 Clinical Trials Mark T. Edwards, Wayne Burkle, Amy Cutrell, Qiming Liao, Cindy Brothers and Jaime E. Hernandez GlaxoSmithKline R&D, RTP, NC, USA Introduction Hematologic abnormalities have been described with HIV infection. The most common abnormality is anemia, which has been associated with advanced HIV disease and reported in 40% of untreated subjects and in 60 to 95% of treated subjects (1-5). Anemia has also been identified as a predictor of decreased HIV disease survival (6). Although HAART has been reported to improve HIV-related anemia, this complication remains relatively common and is associated with fatigue and decreased quality of life; with some studies showing improvement of these parameters after appropriate treatment. Hematologic toxicity (mainly anemia and neutropenia) has been reported in HIV+ subjects, including those treated with ZDV. This ZDV-associated toxicity may be dose related. Approximately 3% of subjects have reported moderate to severe anemia (DAIDS 1992 grades 2 to 4) at the currently approved dose. To better characterize the incidence, severity and determinants of anemia in patients treated with HAART, we performed an analysis of data from 54 trials including more than 12,000 subjects treated with ART with and without ZDV. Methods All GSK-sponsored clinical trials with at least 24 weeks of ART finished from January 1995 to January 2004 and with an authorized database were analyzed. Anemia was identified by hemoglobin (Hb) levels below normal, and classified with the DAIDS 1992 scale. Only subjects with hemoglobin data and a treatment start date were included in this investigation. Descriptive statistics were summarized for naïve and experienced subjects treated with and without ZDV. A retrospective analysis of risk factors for anemia in HIV clinical trials was also conducted. Univariate logistic regression models were fit to understand the individual predictive ability of each potential risk factor. Clinical characteristics used as potential risk factors were: BL demographics, BL CDC Class, BL plasma HIV-1 RNA, BL CD4+ cell count, presence/absence of ZDV in the regimen, BL hemoglobin, BL weight, BL ART status (ART-naïve or ART-experienced), and geographic region (US, Europe, Latin America, or rest of world [ROW]). Post BL hemoglobin results were also classified using the DAIDS 1992 scale; anemia was defined as a hemoglobin value that resulted in a grade 2 or higher classification. Two multivariable logistic regression models were finally constructed using stepwise selection.
2 Results Baseline demographics and characteristics were comparable between subjects treated with (5565 subjects) and without (7075 subjects) ZDV. 65% and 45% of subjects respectively were ART-naïve at BL (Tables 1, 2). The incidence of grade 2/4 anemia in ART-naive subjects was similar in those receiving ZDV (1.5%, 95%CI [1.1%,1.9%]) vs. those not receiving ZDV (1.1%, 95%CI [0.7%,1.5%]). In ART-experienced subjects, the incidence of anemia was higher, (p<0.01), in those receiving ZDV (1.8%, 95%CI [1.2%,2.4%]) vs. those not receiving ZDV (%, 95%CI [0.4%,0.9%]). Severe anemia (grade 3/4) was seen in 1.0% of ART-naïve and in 0.9% of ART-experienced subjects taking ZDV vs. % and 0.3% of subjects not taking ZDV (Table 3). When subjects receiving ZDV were classified as receiving ZDV as a separate drug vs. as part of a fixed combination tablet (Combivir [COM, ZDV 300mg/ Lamivudine 150mg] or Trizivir [TZV, ABC 300mg/ Lamivudine 150mg/ZDV 300mg]) incidences of anemia were 2.0% (95%CI [1.5%,2.5%]) for ZDV and 1.2% (95%CI [0.8%,1.6%]) for COM/TZV (Table 3). Table 1. Baseline Demographics and Characteristics Characteristic N=2616 N=2949 N=7075 N=12640 Age (year, median) Female (%) White (%) ART-Naïve (%) HIV-1 RNA Log 10 copies/ml CD4 + Cells/mm Baseline imbalances between the group of subjects with ZDV and those without ZDV were: Prior ART experience (34% ZDV, 55% no ZDV) and CD4 + cell counts (409 cells/mm 3 ZDV, 290 cells/mm 3 no ZDV). (Table 1). Table 2. Prevalence and Severity of Anemia at BL Hemoglobin N=2616 N=2949 N=7075 N=12640 Normal Grade 1 (%) Grade 2, 3 or 4
3 Table 3. Treatment Emergent Grade 2/4 Anemia Hemoglobin ART-naive N=1649 N=1987 N=3161 N=6797 Grade > 2 (%) Grade > 3 (%) Experienced N=955 N=949 N=3910 N=5814 Grade > 2 (%) Grade > 3 (%) Table 4. Determinants of Anemia in Univariate Models Most Prognostic Explanatory Variables Odds Ratio p-value % with Post-BL Anemia (# with Grade 2 Anemia / N per subgroup) Asian descent % (11/394) Hispanic % (32/1821) Caucasian % (62/7362) Gender (M vs. F) % (M; 101/10161) 1.9% (F; 46/2479) CDC Class (Class C vs. Classes A + B) % (class C; 27/1104) 1.1% (not class C; 92/8795) Age (per 10 yrs) % (<36; 69/5652) 1.1% (>36; 76/6980) Regimen contained ZDV (Y vs. N) % (Y; 87/5565) 0.9% (N; 60/7075) Baseline Viral Load (Log 10 HIV-1 PCR copies/ml) % (<3.9 13/2958) 0.9% ( /3354) % ( /2983) 2.0% (>5.1 63/3152) Baseline CD4+ cell count (per 50 cells) % (<200; 72/3891) 0.8% ( ; 29/3461) 0.8% (>350; 42/5187) Baseline hemoglobin (g/dl) % (Normal or Grade 1; 129/12583) 64.0% (Grade 2 or higher; 16/25) Baseline weight (per 10 kg) % (<62 66/2420) 1.0% (62-<72 30/2912) 0.8% (72-<82 22/2793) 0.7% (>82 19/2568)
4 Among the subjects with hemoglobin data and treatment information, 80% were male, 99% had normal hemoglobin values at baseline, and 46% were ART-experienced (Tables 1 and 2). Global distribution was 49% US, 19% Europe, 3% Latin America, 30% ROW. There were 147 (1.2%) cases of post baseline grade 2-4 anemia as determined by the DAIDS 1992 scale; subjects served as controls. The results of the univariate logistic regression analysis are shown in Table 4 while the results of the 2 multivariable models are shown in Figures 1 and 2. Figure 1. Determinants of Anemia in Multivariable Model 1 Stepwise Logistic Regression (N=12640, n=0 missing) Risk Factor Analysis Multivariable Results Determinants of Grade 2/4 Anemia - Model 1 (N=12,640) OR: 0.54 BL hemoglobin level OR: 2.27 Predictor OR: 6 BL viral load ZDV in the regimen Odds Ratio and 95% Confidence Interval *Edwards, et al. IAS 2005 Figure 2. Determinants of Anemia in Multivariable Model 2 Stepwise Logistic Regression (N=9899, n=2741 missing) Risk Factor Analysis Multivariable Results Determinants of Grade 2/4 Anemia - Model 2 (N=9,899) OR: 0.50 BL hemoglobin level OR: 1.90 Predictor OR: 1.26 BL viral load ZDV in the regimen OR: 1.82 OR: 0.58 Male sex Not from ROW *Edwards, et al. IAS 2005 Odds Ratio and 95% Confidence Interval
5 Discussion Despite significant advances in the treatment of HIV infection, the need for drugs with better long term tolerability and toxicity has been identified. Although effective HAART has been associated with improvement of hematologic complications including anemia, this toxicity remains relatively common. Therefore, comparative safety data in patients treated with HAART with and without ZDV and identification of risk factors for the development of anemia are particularly pertinent. In this analysis using data from more than 12,000 patients participating in 54 controlled clinical trials and with varied characteristics, we were able to demonstrate a low prevalence of anemia at BL and a relatively low incidence of HAART-associated anemia. Although the risk of developing anemia was higher for subjects receiving ZDV-containing HAART, this incidence was also low and appeared lower when COM or TZV were used. Reasons for this finding are not known but may include variability in the BL characteristics that were identified as risk factors for the development of anemia. To identify potential risk factors for the development of anemia in this large cohort, two multivariable models correcting for confounders were constructed. The first model was designed to maximize the number of subjects in the model while the second maximized the number of variables for consideration in the model. Interestingly, both models identified the presence of anemia and a higher viral load at BL as risk factors for subsequent development of anemia regardless of the use of ZDV or not. Ssali et al, recently reported risk factors for the development of severe anemia after ZDV treatment in patients in Africa (7) and also describe BL Hb levels as a determinant; one of our multivariable models identified sex as a potential risk factor but unlike the DART analysis, the risk was higher for males in our cohort. This may be explained by another finding in the same model, namely that subjects from areas similar to those analyzed in DART had a higher risk of anemia vs. other geographic areas. In conclusion, the vast majority of patients treated with HAART +/- ZDV in this cohort did not develop anemia; several risk factors were identified that could be useful when considering ZDV-containing HAART. Conclusion The overall incidence of anemia in this cohort was low (1%). Subjects treated with ZDV had a higher incidence of anemia compared to subjects not treated with ZDV. This incidence, however, was also low and appeared to be lower when COM/TZV were used. Multivariable logistic regression models selected ZDV use, high baseline viral load, and male gender as determinants of increased risk. As expected, higher hemoglobin values at baseline generally suggest a decreased risk of developing anemia. References 1. Coyle T, Med Clin of North Am 1987;81: Sullivan PS, et al. Blood 1998;91: Moore RD and Forney D, J Aquir Immune Defic Synd 2002;19: Semba RD, et at, J Aquir Immune Defic Synd 2001;26: Servais, et al, J Aquir Immune Defic Synd 2001;28: Saah AJ, et al, J Aquir Immune Defic Synd 1994;7: Ssali T, et al, Conference on Retroviruses and Opportunistic Infections, Boston USA Acknowledgements We would like to thank the patients who volunteered to participate in this study and the investigators and coordinators for their support in conducting the study.
43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) A Cutrell, J Hernandez, M Edwards, J Fleming, W Powell, T Scott
43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Poster H-2013 Clinical Risk Factors for Hypersensitivity Reactions to Abacavir: Retrospective Analysis of Over 8,000 Subjects
More informationDifferences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir (TDF)-treated Adults in ESS40006
13th Conference on Retroviruses and Opportunistic Infections Denver, CO, USA. February 5-9, 2006 Poster Number 777 Differences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More information1. Africa Centre for Health and Population Studies 2. London School of Hygiene and Tropical Medicine 3. University College London
A systematic review of the effects of interrupted antiretroviral interventions for prevention of mother-to-child transmission of HIV on maternal disease progression and survival Naidu KK 1, Mori R 2, Newell
More informationNOTICE TO PHYSICIANS. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
NOTICE TO PHYSICIANS DATE: March 10, 2003 TO: FROM: SUBJECT: HIV/AIDS Health Care Providers Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
More informationABC/3TC/ZDV ABC PBO/3TC/ZDV
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAbacavir is associated with increased risk of cardiovascular disease in HIV-infected patients: A UK clinic case-control study
Abacavir is associated with increased risk of cardiovascular disease in HIV-infected patients: A UK clinic case-control study Collins Iwuji, Duncan Churchill, Yvonne Gilleece, Martin Fisher Brighton and
More informationAntiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa
Antiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa Alana T Brennan, Kate Shearer, Mhairi Maskew, Prudence Ive, Ian Sanne, Matthew P Fox Health Economics
More informationThe availability and cost are obstacles to using pvl in monitoring HIV treatment outcomes in resource-constrained settings
Impact of the frequency of plasma viral load monitoring on treatment outcome among perinatally HIVinfected Asian children stable on first-line NNRTI-based cart T Sudjaritruk, DC Boettiger, NV Lam, KAM
More informationTDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia
TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral
More informationHIV/AIDS CLINICAL CARE QUALITY MANAGEMENT CHART REVIEW CHARACTERISTICS OF PATIENTS FACTORS ASSOCIATED WITH IMPROVED IMMUNOLOGIC STATUS
HIV/AIDS CLINICAL CARE QUALITY MANAGEMENT CHART REVIEW CHARACTERISTICS OF PATIENTS WITH LOW CD4 COUNTS IN 2008 AND FACTORS ASSOCIATED WITH IMPROVED IMMUNOLOGIC STATUS FROM 2004 THROUGH 2008 For the Boston
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationFactors associated with unsuppressed viral load in HIV-1 infected patients on 1 st line antiretroviral therapy in South Africa
Factors associated with unsuppressed viral load in HIV-1 infected patients on 1 st line antiretroviral therapy in South Africa Dvora Joseph Davey 1, 2, PhD, Zulfa Abrahams 2, PhD 1 BroadReach, South Africa
More informationFrailty and the Risk of Falls in HIV- Infected Older Adults in the ACTG A5322 Study
Frailty and the Risk of Falls in HIV- Infected Older Adults in the ACTG A5322 Study Katherine Tassiopoulos, Mona Abdo, Susan L. Koletar, Frank Palella, Babafemi Taiwo, and Kristine M. Erlandson for the
More informationHigher Risk of Hyperglycemia in HIV-Infected Patients Treated with Didanosine Plus Tenofovir
6131_06_p333-337 4/5/06 10:28 AM Page 333 AIDS RESEARCH AND HUMAN RETROVIRUSES Volume 22, Number 4, 2006, pp. 333 337 Mary Ann Liebert, Inc. Higher Risk of Hyperglycemia in HIV-Infected Patients Treated
More informationINTERNATIONAL WORKSHOP ON HIV PEDIATRICS - JULY
PHARMACOKINETIC AND 4-WEEK SAFETY/EFFICACY OF DOLUTEGRAVIR (S/GSK1349572) DISPERSIBLE TABLETS IN HIV-INFECTED CHILDREN AGED 4 WEEKS TO
More informationReport Back from CROI 2010
Report Back from CROI 2010 Conference on Retroviruses and Opportunistic Infections Edwin Charlebois, MPH PhD Associate Professor of Medicine Department of Medicine University of California, San Francisco
More informationBHIVA Workshop: When to Start. Dr Chloe Orkin Dr Laura Waters
BHIVA Workshop: When to Start Dr Chloe Orkin Dr Laura Waters Aims To use cases to: Review new BHIVA guidance Explore current data around when to start To discuss: Medical decisions, pros and cons Luigi
More informationPharmacovigilance of highly active antiretroviral therapy among adult patients in a large urban HIV treatment center in Nigeria
Abstract no. A-641-0120-07827 Pharmacovigilance of highly active antiretroviral therapy among adult patients in a large urban HIV treatment center in Nigeria I.O. Abah 1, P. Ugoagwu, V. Ojeh, L. Ogwuche,
More informationHIV AND LUNG HEALTH. Stephen Aston Infectious Diseases SpR Royal Liverpool University Hospital
HIV AND LUNG HEALTH Stephen Aston Infectious Diseases SpR Royal Liverpool University Hospital Introduction HIV infection exerts multiple effects on pulmonary immune responses: Generalised state of immune
More informationFactors Associated with Limitations in Daily Activity Among Older HIV+ Adults
Factors Associated with Limitations in Daily Activity Among Older HIV+ Adults KM Erlandson, K Wu, R Kalayjian, S Koletar, B Taiwo, FJ Palella Jr, K Tassiopoulos and the A5322 Team Background Growing burden
More informationMany highly active antiretroviral therapy PROCEEDINGS
MAXIMIZING THE EFFECTIVENESS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: IS THERE A ROLE FOR QUADRUPLE REGIMENS? * François Raffi, MD, PhD ABSTRACT Although many highly active antiretroviral therapy (HAART)
More informationPrevalence of Comorbidities among HIV-positive patients in Taiwan
Prevalence of Comorbidities among HIV-positive patients in Taiwan Chien-Ching Hung, MD, PhD Department of Internal Medicine National Taiwan University Hospital, Taipei, Taiwan % of participants Comorbidity
More informationPhase II clinical trial TEmAA. Didier Koumavi EKOUEVI, MD PhD (Principal Investigator)
The combination of Tenofovir-Emtricitabine (Truvada ): a new antiretroviral (ARV) regimen for the prevention of mother-to-child transmission of HIV-1 (PMTCT) in resource-limited settings Phase II clinical
More informationEffect of HAART on growth parameters and absolute CD4 count among HIV-infected children in a rural community of central Nigeria
Niger J Paed 2014; 41 (1): 1-6 Ebonyi AO Oguche S Dablets E Sumi B Yakubu E Sagay AS ORIGINAL Effect of HAART on growth parameters and absolute CD4 count among HIV-infected children in a rural community
More informationPredicting mortality in HIV-infected children initiating highly active antiretroviral therapy: A risk scoring system for resource-limited settings
Predicting mortality in HIV-infected children initiating highly active antiretroviral therapy: A risk scoring system for resource-limited settings By James Nugent A Master s Paper submitted to the faculty
More informationDeterminants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus
Determinants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus Leah Burke, M.D. 1, Daniel Fierer, M.D. 2, David Cassagnol,
More informationIndividual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424138
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Atazanavir () Individual Study Table Referring to the Dossier (For National Authority Use Only)
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationThe results of the ARTEN study. Vicente Soriano Hospital Carlos III, Madrid, Spain
The results of the ARTEN study Vicente Soriano Hospital Carlos III, Madrid, Spain Nevirapine: a well-defined efficacy and tolerability profile High efficacy levels 1 3 Well-defined safety profile 4 Favourable
More informationAntiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
More informationSafety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to <6 years: Week 48 analysis of the ARIEL trial
Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to
More informationSimbarashe Takuva, 1 Mhairi Maskew, 2 Alana T. Brennan, 3 Ian Sanne, 1,2 A. Patrick MacPhail, 1,2 and Mathew P. Fox 2,3,4. 1.
Tropical Medicine Volume 2013, Article ID 162950, 6 pages http://dx.doi.org/10.1155/2013/162950 Clinical Study Anemia among HIV-Infected Patients Initiating Antiretroviral Therapy in South Africa: Improvement
More informationDeborah Kacanek, Konstantia Angelidou, Paige L. Williams, Miriam Chernoff, Kenneth Gadow, Sharon Nachman, The IMPAACT P1055 Study Team
Psychiatric disorder symptoms are associated with longitudinal changes in antiretroviral (ARV) non-adherence in perinatally HIV-infected youth in the US: Results from IMPAACT P1055 Deborah Kacanek, Konstantia
More informationAlexander O. Pasternak, Mirte Scherpenisse, Ben Berkhout
Cell-associated HIV-1 unspliced to multiply spliced RNA ratio at 12 weeks ART correlates with markers of immune activation and apoptosis and predicts the CD4 + T-cell count at 96 weeks ART Alexander O.
More informationHIV and Bone Disease: Through Thick and Thin! Pablo Tebas, MD
HIV and Bone Disease: Through Thick and Thin! Pablo Tebas, MD April 30 th, 2016 Disclosures I serve in an adjudication panel in a VZV vaccine study (Glaxo) I consult for Merck My research is supported
More informationImmunologic and Virologic Disease Progression and Response to ART Across Geographic Regions: Outcomes from HPTN 052
Immunologic and Virologic Disease Progression and Response to ART Across Geographic Regions: Outcomes from HPTN 052 Mina C. Hosseinipour, MD, MPH Site Investigator UNC Project, Lilongwe, Malawi UNC School
More informationScottish Medicines Consortium
Scottish Medicines Consortium raltegravir, 400mg film-coated tablet (Isentress) No. (461/08) Merck, Sharp and Dohme Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment
More informationBristol-Myers Squibb
A Study of the Safety and Efficacy of plus Tenofovir in Adults with Chronic Hepatitis B Virus Infection with Previous Nucleoside/Nucleotide Treatment Failure () FINAL CLINICAL STUDY REPORT EUDRACT Number:
More informationGESIDA 2018 ANTIRETROVIRAL TREATMENT MAINTENANCE STRATEGIES AND BLOOD TELOMERE LENGTH CHANGE
ANTIRETROVIRAL TREATMENT MAINTENANCE STRATEGIES AND BLOOD TELOMERE LENGTH CHANGE Rocío Montejano 1, Natalia Stella-Ascariz 1, Susana Monge 1, Jose I Bernardino 1, Ignacio Perez-Valero 1, Marisa Montes
More informationHIV treatment interruptions are associated with heightened biomarkers of inflammation, coagulopathy and T-cell activation despite viral suppression
HIV treatment interruptions are associated with heightened biomarkers of inflammation, coagulopathy and T-cell activation despite viral suppression Nicholas Musinguzi on behalf of Jose Castillo-Mancila,
More informationWHO recommendations for HIVDR surveillance and their application in Latin America and the Caribbean
WHO recommendations for HIVDR surveillance and their application in Latin America and the Caribbean Giovanni Ravasi Pan-American Health Organization, Brazil ravasigi@paho.org Regional Consultation on HIV
More informationLiver Toxicity in Epidemiological Cohorts
SUPPLEMENT ARTICLE Liver Toxicity in Epidemiological Cohorts Stephen Becker Pacific Horizon Medical Group, San Francisco, California Hepatotoxicity has been demonstrated to be associated with antiretroviral
More informationPitavastatin 4 mg vs. Pravastatin 40 mg in HIV Dyslipidemia: Post- Hoc Analysis of the INTREPID Trial Based on the Independent CHD Risk Factor for Age
Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV Dyslipidemia: Post- Hoc Analysis of the INTREPID Trial Based on the Independent CHD Risk Factor for Age Craig A. Sponseller, Masaya Tanahashi, Hideki Suganami,
More informationHPTN 052. Myron S. Cohen, MD Principal Investigator. Presented at the 6 th Int. Workshop on HIV Transmission, July 2011, Rome, Italy
HPTN 052 Myron S. Cohen, MD Principal Investigator Presented at the 6 th Int. Workshop on HIV Transmission, 14 15 July 2011, Rome, Italy Antiviral Treatment as Prevention Extensive biological plausibility
More informationAntiviral Therapy 2016; 21: (doi: /IMP3052)
Antiviral Therapy 2016; 21:725 730 (doi: 10.3851/IMP3052) Short communication HIV viral suppression in TREAT Asia HIV Observational Database enrolled adults on antiretroviral therapy at the Social Health
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Rough K, Seage GR III, Williams PL, et al. Birth outcomes for
More informationSECONDARY OBJECTIVES:
Study No.: 112 419 Title: Retrospective study using the NADIS database of the reasons for discontinuing the Abacavir-Lamivudine combination in HIV-infected patients treated by an antiretroviral regimen
More informationHighly active antiretroviral (ARV) therapy (HAART) has dramatically
ORIGINAL STUDIES Pattern and Predictors of Immunologic Recovery in Human Immunodeficiency Virus-Infected Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor-Based Highly Active Antiretroviral
More informationFrailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting. Giovanni Guaraldi
Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting Giovanni Guaraldi Potential conflicts of interest Research funding: Jansen, Gilead, MSD, BMS Consultancies:
More informationFor any cancer and for infection-related cancer, immediate ART was associated with a lower cancer risk in the first three models but not in models D,
Immediate ART in START Cuts Risk of Infection-Linked Cancer About 75% Conference on Retroviruses and Opportunistic Infections (CROI), February 22-25, 2016, Boston Mark Mascolini People who started antiretroviral
More informationInfertility Treatment and HIV
Infertility Treatment and HIV Infertility Treatment by IVF Or Intra-cytoplasmic Sperm Injections (ICSC) In Chronic HIV-1 Sero- discordant Couples (Poster 670) Retrospective study of outcome of IVF or ICSC
More informationMDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007
MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus
More informationDTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO- Recommended NRTI Backbone
DTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO- Recommended NRTI Backbone Aboud M, 1 Brites C, 2 Lu H, 3 Supparatpinyo K, 4 Hercilla L, 5 Sievers J, 1 Nascimento MC, 1 Hopking J, 6 Underwood
More informationWhole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy
Whole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy K El Bouzidi 1,, RP Datir 1, V Kwaghe 3, S Roy 1, D Frampton
More informationSeble G. Kassaye, M.D., M.S. Assistant Professor of Medicine Division of Infectious Diseases and Travel Medicine Georgetown University
Seble G. Kassaye, M.D., M.S. Assistant Professor of Medicine Division of Infectious Diseases and Travel Medicine Georgetown University November 5, 2016 None HIV epidemiology Global U.S. Washington, D.C.
More informationRetention in HIV care predicts subsequent retention and predicts survival well after the first year of care: a national study of US Veterans
Retention in HIV care predicts subsequent retention and predicts survival well after the first year of care: a national study of US Veterans Thomas P. Giordano, MD, MPH, Jessica A. Davila, PhD, Christine
More informationHIV-HBV coinfection in HIV population horizontally infected in early childhood between
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE HIV-HBV coinfection in HIV population horizontally infected in early childhood between 1987-1990 Supervising professor: Prof. Cupşa Augustin
More informationEffectiveness of highly active antiretroviral therapy using non-brand name drugs in Brazil
Brazilian Journal of Medical and Biological Research (2007) 40: 551-555 Effectiveness of non-brand name drugs ISSN 0100-879X 551 Effectiveness of highly active antiretroviral therapy using non-brand name
More informationOUTCOMES OF HIV-INFECTED THERAPY INCLUDING
UNIVERSIDADE FEDERAL DA BAHIA FACULDADE DE MEDICINA DA BAHIA PROGRAMA DE PÓS-GRADUAÇÃO EM MEDICINA E SAÚDE OUTCOMES OF HIV-INFECTED PATIENTS RECEIVING RESCUE THERAPY INCLUDING RALTEGRAVIR Patino-Escarcina
More informationSYNOPSIS. Clinical Study Report AI Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product:
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Sustiva /Stocrin Name of Active Ingredient: efavirenz Individual Study Table Referring to the Dossier (For National Authority Use
More informationCryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease
Cryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease Assist Prof. Somnuek Sungkanuparph Division of Infectious Diseases Faculty of Medicine Ramathibodi Hospital Mahidol
More informationProteinuria, Creatinine Clearance, and Immune Activation in Antiretroviral- Naive HIV-Infected Subjects
BRIEF REPORT Proteinuria, Creatinine Clearance, and Immune Activation in Antiretroviral- Naive HIV-Infected Subjects Samir K. Gupta, 1 Lauren Komarow, 2 Roy M. Gulick, 4 Richard B. Pollard, 5 Gregory K.
More informationICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
More informationAntiviral Therapy 2013; 18: (doi: /IMP2329)
Antiviral Therapy 2013; 18:213 219 (doi: 10.3851/IMP2329) Original article Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the
More informationIntroduction. Cahn et al. Andean Pacific HIV Clinical Forum 2017; Santiago, Chile. Abstract 2.
Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Fixed Dose Combination (FDC) Compared With Ritonavir- Boosted Atazanavir (ATV/r) Plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in
More informationANTIRETROVIRAL (ART) DRUG INFORMATION FOR HEALTH CARE PROFESSIONAL
ZIDOVUDINE (AZT, Retrovir ) Benefits of zidovudine: Zidovudine (ZDV) is an antiretroviral drug that slows the growth of the HIV virus. It has shown in a large randomized, multicentre study to decrease
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationReferences: 1. XVI International AIDS Conference, 2006 Abstract no. ThPE0120 2. Bergshoeff A, Burger D, Farrelly L e t al. Pharmacokinetics of once daily vs. twice daily lamivudine and abacavir in HIV-Infected
More informationSupervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis.
Supervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis. J.L. YOZVIAK 1, P. KOUVATSOS 2, R.E. DOERFLER 3, W.C. WOODWARD 3 1 Philadelphia College of Osteopathic
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationCD4 + T. antiretroviral therapy ART CD4 + T. Kaplan-Meier
2018 12 22 12 1229 HIV /AIDS CD4 + T 1 1 1 2 1 1 1 1 1 1 1 1 1 / human immunodeficiency virus /acquired immunodeficiency syndrome HIV /AIDS antiretroviral therapy ARTCD4 + T CD4 ART HIV /AIDS ART CD4 ART
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationActive TB in HIV-infected children in Thailand: Prevalence, incidence and mortality
O_17 Active TB in HIV-infected children in Thailand: Prevalence, incidence and mortality N. Salvadori 1, P. Riyaten 1, S. Thongsak 1, S. Chalermpantmetagul 1, P. Traisathit 1,2, C. Ngampiyaskul 3, S. Hanpinitsak
More informationSupplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time.
Supplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time. Anne Cori* 1, Michael Pickles* 1, Ard van Sighem 2, Luuk Gras 2,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDepression in People Living with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention
The Alfred Hospital Depression in People Living with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention Final Report August 2005 Chief Investigator Associate Professor Anne Mijch Infectious Diseases
More informationSUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart.
Supplementary Figure S1. Cohort definition flow chart. Supplementary Table S1. Baseline characteristics of study population grouped according to having developed incident CKD during the follow-up or not
More informationSYNOPSIS Final Clinical Study Report for Study AI444031
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHormonal Contraception Use and Non-AIDSdefining
Hormonal Contraception Use and Non-AIDSdefining Events Vlada Melekhin, MD, MPH January 10, 2012 Vanderbilt University Outline Background Methods Results Conclusions Limitations Future Directions Hormonal
More informationA Genetic Test to Screen for Abacavir Hypersensitivity Reactions
The Future of Pharmacogenetics in HIV Clinical Care A Genetic Test to Screen for Abacavir Hypersensitivity Reactions Evan Collins & Misty Bath CANAC/ACIIS 15 th Annual Conference Vancouver, BC April 2007
More informationOutline. Epidemiology of Pediatric HIV 10/3/2012. I have no financial relationships with any commercial entity to disclose
Nutritional, Metabolic, and Gastrointestinal Complications in Pediatric HIV Infection Tracie L. Miller, MD Department of Pediatrics University of Miami, Miller School of Medicine I have no financial relationships
More informationSupplementary Material*
Supplementary Material* Park LS, Tate JP, Sigel K, Brown ST, Crothers K, Gibert C, et al. Association of Viral Suppression With Lower AIDS-Defining and Non AIDS-Defining Cancer Incidence in HIV-Infected
More informationTable S1. Number of eligible individuals by cohort, HIV-CAUSAL and CNICS Collaborations,
Cohort Table S1. Number of eligible individuals by cohort, HIV-CAUSAL and CNICS Collaborations, 2000-2013 No. of antiretroviraltherapy naïve individuals No. initiated cart regimen in 2000 or later No.
More informationPre-eclampsia and HIV. Matjies river. David Hall Department of O&G Stellenbosch University
Pre-eclampsia and HIV Matjies river David Hall Department of O&G Stellenbosch University Background HIV + hypertensive diseases - important conditions Both related to maternal and perinatal morbidity and
More informationDOI: /hiv British HIV Association HIV Medicine (2014), 15, ORIGINAL RESEARCH
DOI: 0./hiv.22 ORIGINAL RESEARCH A simplified combination antiretroviral therapy regimen enhances adherence, treatment satisfaction and quality of life: results of a randomized clinical trial N Langebeek,
More informationTransient viral load increases in HIV-infected children in the UK and Ireland: what do they mean?
Transient viral load increases in HIV-infected children in the UK and Ireland: what do they mean? Katherine J Lee 1 *, Delane Shingadia 2, Deenan Pillay 3, A Sarah Walker 1, Andrew Riordan 4, Esse Menson
More informationGender Disparities in Viral Suppression and Antiretroviral Therapy Use by Racial and Ethnic Group Medical Monitoring Project,
Gender Disparities in Viral Suppression and Antiretroviral Therapy Use by Racial and Ethnic Group Medical Monitoring Project, 2009-2010 Linda Beer PhD, Christine L Mattson PhD, William Rodney Short MD,
More informationPharmacy refill data can be used to predict virologic failure for patients on antiretroviral therapy in Brazil
Short report Pharmacy refill data can be used to predict virologic failure for patients on antiretroviral therapy in Brazil David Martin 1, Paula M. Luz 2, Jordan E. Lake 3, Jesse L. Clark 3, Dayse P.
More informationHIV viral load testing in the era of ART. Christian Noah Labor Lademannbogen, Hamburg
HIV viral load testing in the era of ART Christian Noah Labor Lademannbogen, Hamburg 1 Life expectancy of patients on ART Data from the UK Collaborative HIV Cohort (UK CHIC) Requirements: Early diagnosis
More informationFACTORS AFFECTING RESPONSE TO ANTIRETROVIRAL AGENTS AT ONE YEAR IN AN HIV COHORT AT ROMA HOSPITAL, LESOTHO
FACTORS AFFECTING RESPONSE TO ANTIRETROVIRAL AGENTS AT ONE YEAR IN AN HIV COHORT AT ROMA HOSPITAL, LESOTHO BY ADEBANJO ADEFOLARIN BABAFEMI Submitted in partial fulfilment of the requirements for the degree
More informationImmunologic Failure and Chronic Inflammation. Steven G. Deeks Professor of Medicine University of California, San Francisco
Immunologic Failure and Chronic Inflammation Steven G. Deeks Professor of Medicine University of California, San Francisco Plasma HIV RNA (log) 6 5 4 3 2 52 year old HIV+/HCV+ man presents with symptomatic
More informationTenofovir plasma exposures and Creatinine Clearance changes in 1st line Regimen of African patients in Cameroon and Senegal: ANRS12115 DAYANA study
Abstract O_03 Tenofovir plasma exposures and Creatinine Clearance changes in 1st line Regimen of African patients in Cameroon and Senegal: ANRS12115 DAYANA study M.P. Lê Pharmacy Resident Clinical Pharmacology
More informationSupervivencia a 5 años de Pacientes Coinfectados por VHC-VIH Trasplantados Hepáticos: un Estudio de Casos y Controles
I Congreso de GESIDA Madrid, 21-24 de Octubre del 2009. Supervivencia a 5 años de Pacientes Coinfectados por VHC-VIH Trasplantados Hepáticos: un Estudio de Casos y Controles José M. Miró, 1 Miguel Montejo,
More informationAttrition and Treatment Outcomes among Perinatally and Behaviourally HIV-infected Adolescents and Youths in Thai National AIDS program
Attrition and Treatment Outcomes among Perinatally and Behaviourally HIV-infected Adolescents and Youths in Thai National AIDS program Sirinya Teeraananchai 1,2, Thanyawee Puthanakit 1,3,4, Suchada Chaivooth
More informationCascade of medical care to HIV-infected patients in Europe. Cristina Mussini
Cascade of medical care to HIV-infected patients in Europe Cristina Mussini UNAIDS: New HIV treatment target 90% of people tested 90% of people diagnosed with HIV on treatment 90% of people on treatment
More informationUpdates on Revised Antiretroviral Treatment Guidelines Overview 27 March 2013
Updates on Revised Antiretroviral Treatment Guidelines 2013 Overview 27 March 2013 Introduction of Fixed Dose combination (FDC) FDCs will be available in facilities on 1 April 2013 The FDC ARV that will
More information